Topic
Pharmaceutical Promotion
152 published works
BioSlice Blog
UK PMCPA publishes revised guidance for the use of social media
By Libby Amos-Stone, Katya Farkas
The Prescription Medicines Code of Practice Authority (PMCPA) has published revised guidance on social media. Social media has remained a significant focus for the PMCPA in recent years, with numerous…
As Prescribed
UK PMCPA Refreshes Social Media Guidance: What In-House Teams Should Know
By Morgan Lewis
The UK Prescription Medicines Code of Practice Authority (PMCPA) has published revised social media guidance in a new dedicated section of its website , reflecting recent case precedent and the…
Patent Law Weblog
Supreme Court to Resolve Dispute Over Marketing of “Skinny Labeled” Generics
By Joshua Rich and Kevin E. Noonan – The Hatch-Waxman Act has always represented a delicate balance between the interests of innovator and generic drugmakers: innovators seek to maintain exclusivity…
Food, Drug & Agriculture
FDA Continues Crack Down on DTC Advertising: Untitled Letter Highlights Pitfalls in Schizophrenia Drug Promotion
By Dominick DiSabatino, Julian Klein
Just in time for the holidays, on December 15, 2025, the U.S. Food and Drug Administration (“FDA”) Office of Prescription Drug Promotion (“OPDP”) issued an untitled letter (the “Letter”) to…
Agricultural Law & Rural Practice | Solo Small Firm & General Practice Section
A Turning Point for OPDP: What 2025 Enforcement Activity Signals for 2026
By Hall Render
Until this year, the Food and Drug Administration’s (FDA or agency) Office of Prescription Drug Promotion (“OPDP”) enforcement activity had settled into a relatively predictable pattern. In both 2023 and…
Food, Drug & Agriculture
What to Watch: Continued DTC Advertising Enforcement
By Dominick DiSabatino, Audrey Mercer
Just before Thanksgiving, the Food and Drug Administration’s (“FDA’s”) Office of Prescription Drug Promotion (“OPDP”) silently published three untitled letters, furthering this administration’s promise to crack down on direct-to-consumer (“DTC”)…
Drug & Device Law
FCA Dismissal Illustrates Pharmaceutical Promotion Done Right
By Bexis
Back in the bad old days of the Bone Screw litigation, we had to fight our way through a thicket of scurrilous allegations about how our clients supposedly promoted off-label…
Food, Drug & Agriculture
FDA Ratchets Enforcement on Social Media Promotion in New Warning Letter
By Dominick DiSabatino, Julian Klein
This week, the U.S. Food and Drug Administration (“FDA”) Office of Prescription Drug Promotion (“OPDP”) posted a warning letter (the “Letter”)[1], issued on May 29, 2025, to Sprout Pharmaceuticals, Inc.…
Health Care and Life Sciences
Reminder: FDA Does, In Fact, Review DOF
By Dominick DiSabatino, Julian Klein
When was the last time you thought about “data on file” (“DOF”)? Probably not recently, but last week, the U.S. Food and Drug Administration (FDA) Office of Prescription Drug Promotion…
China Law Insight
警惕“异化”灵活用工，揭开医药领域发票虚开的真相丨医药营销合规系列（一）
By King & Wood
作者：吴巍 朱媛媛 赵妍 今年11月4日，央视《今日说法》栏目播出“被隐匿的真相”，曝光了震惊全国的内蒙古乌兰浩特60亿特大虚开案件。内蒙古乌兰浩特公安根据公安部提供的线索发现，2018年至2021年初，乌兰浩特本地的40多家空壳公司为全国多个药企虚开1.6亿元发票。警方在全国范围内又关联查询了四千多家类似的公司，累计虚开发票60亿元。 节目阐述了部分医药企业以虚高的价格卖出药品，医药代理商控制空壳CSO公司虚构市场推广服务并向医药生产企业虚开推广服务费发票，套取高额利润，最终以回扣方式输送给医院相关人员，以促进药品销量。 阅读更多